FDA Accepts First Biosimilar Application Filed under Section 351(k) of the Public Health Service Act

by K&L Gates LLP
Contact

Biologics are large molecules made from, derived from, or extracted from a natural source such as a human, animal, or microorganism that are used in the treatment, diagnosis, or prevention of disease. Biologics include therapeutic proteins, DNA vaccines, monoclonal antibodies, and fusion proteins. A biosimilar is best characterized as a similar but not identical copy of a biologic that has previously been granted marketing authorization by the FDA. Minor differences between a biosimilar and a biologic may exist and are likely most often due to the variation in the processes used in their manufacture and are permitted so long as any differences are demonstrated not to be clinically significant.

The Biologics Price Competition and Innovation Act (BPCIA) was enacted in 2010 as part of the Patient Protection and Affordable Care Act and amended the Public Health Service Act (PHSA) to establish an expedited pathway for FDA approval of biosimilars (often referred to as “follow-on biologics”). This expedited pathway requires an applicant to submit an application containing detailed information about their biosimilar, including analytical studies showing that their biosimilar is highly similar to a branded biologic already approved by the FDA; animal studies that include an assessment of toxicity; and a clinical study or studies demonstrating the safety, purity, and potency of the biosimilar. Such requirements have been the subject of several guidances from the FDA intended to provide recommendations to applicants on the scientific and technical information of the chemistry, manufacturing, and controls (CMC) section of a marketing application for a proposed biosimilar product submitted under section 351(k) of the PHSA. Additionally, the BPCIA sets forth a detailed procedure and timeline where a holder of a branded biologic and a biosimilar applicant are to engage in a series of exchanges of information with the goal of determining which if any of the brand holder’s patents will be litigated by the parties. To date, this expedited pathway for FDA approval of a biosimilar has yet to yield any approved biosimilars.

On July 24, 2014, over four years after the enactment of the BPCIA, the FDA accepted its first biosimilar application from Sandoz Inc. (“Sandoz”). Sandoz’s application is for a biosimilar version of Amgen Inc.’s (“Amgen”) Neupogen® (filgrastim). Neupogen® is a pharmaceutical analog of human granulocyte colony stimulating factor that is used to treat neutropenia, a condition where the body does not make enough neutrophils, a type of white blood cell. Amgen’s Neuprogen® is indicated for use by patients receiving strong chemotherapy to reduce their risk of infection.

Sandoz’s biosimilar application is set to provide future applicants a wealth of information and, most importantly, with clarity around the FDA review process. For example, as part of filing its application, Sandoz will be required to engage in an exchange of manufacturing information with Amgen to resolve which, if any, of Amgen’s patents that cover Neupogen® will be litigated by the parties, and which, if any, patents will not be litigated by the parties. As the first biosimilar application to be subjected to these procedures, it will be interesting to see how the information exchange between Sandoz and Amgen plays out and what, if any, litigation arises as a result. Additionally, if Sandoz’s application is approved, it should provide clarity regarding the appropriate naming convention to use for biosimilars. Currently, there is an ongoing debate as to how biosimilars should be named. Branded biologic holders often assert that biosimilars should have distinct generic names; whereas, the biosimilar holders often assert that having distinct names will confuse patients into thinking that the biosimilar is not as safe or effective as the branded biologic. Further, the timeliness of the FDA’s decision on Sandoz’s application will indicate whether it will be possible for the FDA to meet its goal of reviewing 70% of new applications within 10 months for fiscal year 2014, as set forth in the FDA’s Biosimilar Biological Product Authorization Performance Goals and Procedures Fiscal Years 2013 through 2017.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© K&L Gates LLP | Attorney Advertising

Written by:

K&L Gates LLP
Contact
more
less

K&L Gates LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Privacy Policy (Updated: October 8, 2015):
hide

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.

Security

JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.
Feedback? Tell us what you think of the new jdsupra.com!